Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes.
J Obes Metab Syndr · 2021
Last updated 2026-08-29Liraglutide is a drug used to treat type 2 diabetes and, at a higher dose, for weight control. Studies show mixed results about its safety, with some reporting it as effective and safe while others highlight risks. The review examines side effects linked to liraglutide, noting that real-world use may increase adverse reactions if the drug is prescribed more broadly than intended.
AI summary of the abstract below.
| Journal | J Obes Metab Syndr, 2021 |
|---|---|
| Citations | 35 |
| Relative citation ratio | 2.49 |
| NIH percentile | 80 |
| Molecules | liraglutide |
Abstract
Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore, it is necessary to consider adverse reactions of the drug at high doses as well as at lower doses after the indication has been expanded. Body mass index criteria for patients prescribed the drug in the real world tend to be applied less rigorously, which may increase the number of adverse reactions due to over-prescription. Liraglutide treatment was found effective and safe in some studies, while others have warned about its risks. Therefore, this review summarizes the current data available on side effects associated with liraglutide.
Verbatim abstract via PubMed 33071241 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.